Abstract: Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of identifying anti-cancer compounds that target oncogenic dimeric proteins. Exemplary compounds that can be used in the disclosed methods of treatment and pharmaceutical compositions have the chemical structures disclosed in the specification.

Abstract: Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents.

Abstract: A multi-level buck converter includes an input power source, an input capacitor, first to fourth switches, a clamp capacitor, an output inductor, a clamp switch, a clamp diode, an output capacitor, an output load, a current detection circuit, a voltage detection circuit and a control circuit. The current detection circuit detects whether an inductor current of the output inductor exceeds a predetermined current value, and if so, the output clamp signal controls the clamp switch to be turned on. The voltage detection circuit generates a duty cycle control signal according to an error between an output voltage and a target output voltage. The control circuit controls the first to the fourth switches to sequentially enter a first mode, a second mode, a third mode, and a fourth mode in a first part of a duty cycle.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: A MEMS device is provided. The MEMS device includes a substrate having at least one contact, a first dielectric layer disposed on the substrate, at least one metal layer disposed on the first dielectric layer, a second dielectric layer disposed on the first dielectric layer and the metal layer and having a recess structure, and a structure layer disposed on the second dielectric layer and having an opening. The opening is disposed to correspond to the recess structure, and the cross-sectional area at the bottom of the opening is smaller than the cross-sectional area at the top of the recess structure. The MEMS device also includes a packaging layer, and at least a portion of the packaging layer is disposed in the opening and the recess structure. The second dielectric layer, the structure layer, and the packaging layer define a chamber.

Abstract: A full bridge converter having a wide output voltage range includes an input power source, a full bridge switching circuit, a transformer, a first rectifying circuit, a second rectifying circuit, a first output circuit, a second output circuit, and a control circuit. The transformer includes a magnetic core, a primary side winding, a first secondary side winding, and a second secondary side winding. The first rectifying circuit includes a first AC switch, a second AC switch and a first freewheeling diode, and the second rectifying circuit includes a third AC switch, a fourth AC switch and a second freewheeling diode. The control circuit, according to a duty cycle, controls the first AC switch and the third AC switch to be turned on during a positive half cycle, and controls the second AC switch and the fourth AC switch to be turned on during a negative half cycle.

Abstract: A totem-pole bridgeless power factor corrector and a power factor correction method are provided. The totem-pole bridgeless power factor corrector obtains a duty cycle of next state by a predictive valley-peak current control method, and uses an OR gate element to combine PWM signals generated by an average current control method and the predictive valley-peak current control method, thereby enabling a digital signal processor to update the duty cycle.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided is an underwater repair system for a cavity region of a concrete panel rock-fill dam panel, including a moving platform, a work cabin, a pressure drainage apparatus, a traction apparatus, and a positioning apparatus; the traction apparatus controlling the movement of the moving platform on the surface of a dam concrete panel; the positioning apparatus transmits a detection position, the work cabin is a pressure cabin, the work cabin being connected to the pressure drainage apparatus, and a drill apparatus and grouting apparatus being arranged in the work cabin; the moving platform moves into the cavity region, and the pressure drainage apparatus starts up to drain the water in the work cabin, a partially closed waterless space being formed inside the work cabin, the drill apparatus drilling the concrete panel at the upper end of the cavity region and the grouting apparatus subsequently implementing grouting to complete the repair.

Abstract: A multi-level buck converter includes an input power source, an input capacitor, first to fourth switches, a clamp capacitor, an output inductor, a clamp switch, a clamp diode, an output capacitor, an output load, a current detection circuit, a voltage detection circuit and a control circuit. The current detection circuit detects whether an inductor current of the output inductor exceeds a predetermined current value, and if so, the output clamp signal controls the clamp switch to be turned on. The voltage detection circuit generates a duty cycle control signal according to an error between an output voltage and a target output voltage. The control circuit controls the first to the fourth switches to sequentially enter a first mode, a second mode, a third mode, and a fourth mode in a first part of a duty cycle.

Abstract: A full bridge converter having a wide output voltage range includes an input power source, a full bridge switching circuit, a transformer, a first rectifying circuit, a second rectifying circuit, a first output circuit, a second output circuit, and a control circuit. The transformer includes a magnetic core, a primary side winding, a first secondary side winding, and a second secondary side winding. The first rectifying circuit includes a first AC switch, a second AC switch and a first freewheeling diode, and the second rectifying circuit includes a third AC switch, a fourth AC switch and a second freewheeling diode. The control circuit, according to a duty cycle, controls the first AC switch and the third AC switch to be turned on during a positive half cycle, and controls the second AC switch and the fourth AC switch to be turned on during a negative half cycle.

Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Abstract: A totem-pole bridgeless power factor corrector and a power factor correction method are provided. The totem-pole bridgeless power factor corrector obtains a duty cycle of next state by a predictive valley-peak current control method, and uses an OR gate element to combine PWM signals generated by an average current control method and the predictive valley-peak current control method, thereby enabling a digital signal processor to update the duty cycle.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: A combination for improving intestinal micro-ecology and preventing chronic diseases includes an inulin, a galactooligosaccharide and a dietary fiber composite, wherein the ratio of the inulin, the galactooligosaccharide and the dietary fiber composite in a formula is (1-75):(1-75):(5-95). Preferably, the ratio is (10-50):(10-50):(25-50). A balanced nutritious food includes cereal flour and the ratio of the cereal flour to the combination in a formula is (50-95):(5-50). Preferably, the ratio is (70-95):(30-5). Moreover, provided is an application in preparing foods or medicaments for preventing inflammatory bowel disease, improving gastrointestinal motility and preventing constipation, preventing diabetes, preventing cardiovascular and cerebrovascular diseases, and regulating intestinal flora to enhance immune ability.

Abstract: A suspension particle sensing apparatus includes a first flow channel, a suspension particle concentration sensor and a suspension particle filtering assembly. The first flow channel has a first entrance and a first exit. The suspension particle concentration sensor is disposed in the first flow channel, and is located between the first entrance and the first exit. The suspension particle filtering assembly is disposed at the first entrance, and includes a casing and a suspension particle filtering structure. The casing has a first opening and a second opening. The first opening is communicated with the first entrance of the first flow channel. The suspension particle filtering structure covers the second opening.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Abstract: Provided is a residual toxicant detection system and a residual toxicant detection method, the residual toxicant detection method including: allowing an aqueous solution containing a residual toxicant to flow into a detection portion including a cavity; providing at a side of the cavity a light containing a specific wavelength range to react with the residual toxicant; receiving the light that passes through the cavity on another side of the cavity, thereby generating a sensing signal; and calculating an amount of change in absorbance of the aqueous solution according to the sensing signal, wherein when the amount of change in absorbance is less than a threshold value, a detection count is accumulated, and when the accumulated detection count is greater than a predetermined value, a detection result is generated. Therefore, whether or not the residual toxicant on the object is cleaned can be determined easily and accurately.